Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
about
Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patientsExperience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseasesBiosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.CT-P13: design, development, and place in therapyEffectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.The Role of Biosimilars in Inflammatory Bowel Disease.Insights on the use of biosimilars in the treatment of inflammatory bowel disease.Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.Maintenance therapy options for ulcerative colitis.A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business.Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.Biosimilars in inflammatory bowel disease: A review of post-marketing experience.Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease.European Experience of Infliximab Biosimilars for the Treatment of Inflammatory Bowel Disease.The efficacy and safety of the biosimilar product (Inflectra®) compared to the reference drug (Remicade®) in rescue therapy in adult patients with ulcerative colitis.Comparative effectiveness of the biosimilar CT-P13.Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply.Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort.Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.Biosimilar and innovator anti-Tumour Necrosis Factor (TNF) or lymphocyte trafficking blockade: Which one to select?
P2860
Q26748630-64321317-CFFA-4984-984A-560A5EFF6470Q28066776-C92FBA21-18E0-4638-AC3B-8BF59CE6ABF6Q30393052-792870A3-2491-4C9B-9E4C-2F16732656DEQ30397234-2C14527E-DB1F-498A-92BA-26E46FE04727Q33803728-719FDFAC-5E3B-418F-BAA6-E2252E11A7EDQ33843746-BDECFB5A-62B0-479D-97EE-17C1746442FAQ37540190-A6CEDDCA-DFD8-4F90-8001-FD069FD01D9AQ38735477-FD676F0B-2122-45DA-8009-59C1ADC3CDA8Q38786144-C589AEA2-48ED-4A14-B04B-EE8A27255CBFQ38848140-5DB83E29-1E88-43A7-A0E6-78DEF216EC99Q38937842-66633335-183D-42EC-AC89-F1CB1D466F52Q38960108-2E8A2111-878A-41A6-9C88-19176915EC3FQ38977625-CF0C94EF-0265-4293-BF0F-9F9F03EFEA8FQ38994573-3004972C-B7BF-4C68-AD5F-3D74C70F28DEQ38996437-E2B30260-8E14-4D9F-896F-816A16B6508DQ39016810-2F97D903-ED2C-421A-A53C-0CDC300C809BQ39018436-CD4E2E96-65C6-4D04-AF24-5016B2B581C2Q39051341-A22C6C5D-CCE3-4D3F-984B-93CD138CF2A4Q39152159-4BB4A7B8-0848-43C7-8C3A-CCACAB9B2DB5Q39192318-7C926F7F-28DA-450B-8149-8275500BE20CQ39359495-5936A685-5416-474E-8764-20EF3BF8E310Q40233716-C3646B7D-98C4-4D26-9352-E142D05F5C0AQ41504139-F4C71883-CAD7-44E7-AF41-CD02A49A0D65Q44529123-00805C73-E97A-433F-9F89-21E85EA4F791Q47418286-07909C46-FE59-4E32-AB34-5B5332AE8997Q47662817-E91A6940-5404-49A3-BB99-AE5A248F40C0Q47785572-71168FD9-3EBC-4C13-B30B-38936FE81F0DQ48217871-943F28ED-E8D1-4DF7-B25B-3698DAF5BA4DQ51280643-9FDA98C7-D64F-4858-AE96-5970B808D1E8Q51715018-EF50BD38-668C-442F-81D1-6E48C59CB575
P2860
Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Biosimilar infliximab (CT-P13) ...... Norwegian observational study.
@en
Biosimilar infliximab
@nl
type
label
Biosimilar infliximab (CT-P13) ...... Norwegian observational study.
@en
Biosimilar infliximab
@nl
prefLabel
Biosimilar infliximab (CT-P13) ...... Norwegian observational study.
@en
Biosimilar infliximab
@nl
P2093
P2860
P1476
Biosimilar infliximab (CT-P13) ...... Norwegian observational study.
@en
P2093
Jørgen Jahnsen
Petr Ricanek
Simen Vatn
Trond Espen Detlie
P2860
P356
10.1586/17474124.2015.1091308
P478
P577
2015-01-01T00:00:00Z